Q4FY21 revenues grew 16.3% YoY to | 1839 crore. Biosimilars grew 53.2% YoY to | 664 crore due to low base effect. Research services segment grew 8.4% YoY at | 659 crore. Generic sales grew 2.7% YoY to | 578 crore due to pricing pressure and stockpiling by customers in H1FY21. EBITDA margins improved 355 bps YoY to 23.7% mainly due to strong gross margins and lower R&D; cost. EBITDA grew 36.8% YoY to | 436 crore vs. I-direct estimate of | 470 crore. Adjusted PAT grew 96.6% YoY to | 243 crore. Delta vis--vis EBITDA was due to higher other income, which included | 160 crore gain...